Kellie Rademacher explores the complex world of biomarker testing including the several testing options available, the expansion of biomarkers, and the resulting challenges for various stakeholders.
Rare and orphan drug therapies have had exponential growth in the last decade. Kellie Rademacher explores their costs and impact to payers and the overarching healthcare systems, as well as value-based agreements that are being explored to pay for these therapies.
The CMS has announced that individual markets, small and large group, and self-insured group health plans will be allowed to implement copay accumulator programs starting in 2020. What does this mean for market access? Kellie Rademacher provides an overview.
Kellie Rademacher and Hetty Lima from the Payer Access Solutions team provide guidance into evaluation and valuation in the orphan drug space, currently one of the most active areas of drug development. With the FDA working to streamline the approval process for innovative orphan drugs, there is much promise on the horizon for providing breakthrough treatments, but also unique challenges with payers with regard to pricing and value.